Share
Jeannie Lee
Dr. Lee is currently the Phillip A. Sharp, PhD, Endowed Chair in Molecular Biology and Acting Chair of the Department of Molecular Biology at Massachusetts General Hospital. She also holds a professorship in Genetics and Pathology at Harvard Medical School. Renowned for her pioneering work in RNA Biology and its therapeutic applications, Dr. Lee co-founded Translate Bio and Fulcrum Therapeutics, which focus on RNA and epigenetic therapies.
Her accolades include memberships in the National Academy of Sciences and the National Academy of Medicine, as well as awards such as the Lurie Prize from the Foundation for the National Institutes of Health and the Centennial Prize from the Genetics Society of America. She has also served on the Board of the Genetics Society of America.
Sir Jonathan Symonds, Chair of GSK, commented, “We are thrilled to welcome Jeannie to GSK. Her expertise in RNA biology and epigenetics aligns closely with GSK’s R&D strategy. Her extensive experience in scientific and medical innovation will provide valuable insights to our Board.”
Dr. Lee’s appointment follows an extensive search and selection process conducted by the Nominations & Corporate Governance Committee, with the assistance of an external search firm. She has been confirmed as an independent Non-Executive Director under the UK Corporate Governance Code.
Dr. Lee will receive a standard basic fee of £118,352 per annum, plus £30,000 annually for her role as a scientific and medical expert. She will also be required to meet GSK’s share ownership requirements for Non-Executive Directors.
On her appointment, Dr. Lee will join the Science and Corporate Responsibility committees. She will not have a service contract but will have a letter of appointment available for review through the Company Secretary.
